Home/Pipeline/RESP® Biosensor Evaluation (with Rutgers Health)

RESP® Biosensor Evaluation (with Rutgers Health)

Cystic Fibrosis

Research StudyActive

Key Facts

Indication

Cystic Fibrosis

Phase

Research Study

Status

Active

Company

Strados Labs

About Strados Labs

Strados Labs is a Philadelphia-based digital health company founded in 2018, focused on transforming respiratory monitoring through its FDA 510(k)-cleared and CE-marked RESP® Platform. The company's core technology is a discreet, wearable biosensor that continuously captures high-fidelity lung sounds and physiological data, which is then analyzed in the cloud for clinical and research applications. Strados primarily serves the life sciences industry by providing digital endpoints for respiratory clinical trials and is expanding into remote patient monitoring, with its technology validated and deployed across numerous global clinical sites.

View full company profile

Therapeutic Areas

Chronic Cough Pulmonary Fibrosis Bronchiectasis COPD Asthma Infectious Diseases Lung Cancer Congestive Heart Failure Cystic Fibrosis

Other Cystic Fibrosis Drugs

Drug	Company	Phase	Status
CB-280	Calithera Biosciences	Preclinical/Phase 1	Discontinued
Ensifentrine	Verona Pharma	Phase 2	Under MSD
ALTA Drug Series	Alteron Therapeutics	Preclinical	Research
ColiFin®	Spexis	Marketed (EU)	Active
Cystic fibrosis (CRISPR)	GeneToBe	Discovery	Active
Cystic fibrosis (undisclosed)	GeneToBe	Early Discovery	Active
SM001 (alidornase/Tigerase)	SarcoMed USA	Research	Active
Targeted Lung Delivery	Nanite	Pre-clinical	Active
CFTR 100+ Panel	Agena Bioscience	Commercial	Active
RIG-301 CFTR	RIGImmune	Pre-clinical	Active
CBN-101	Carbon Biosciences	Preclinical	Active
KIT2014	Kither Biotech	Phase 2	Active